Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues

Journal of the American Chemical Society

Volumn 131, Issue 13, 2009, Pages 4904-4916

  Ishikawa, Hayato ^a   Colby, David A ^a   Seto, Shigeki ^a   Va, Porino ^a   Tam, Annie ^a   Kakei, Hiroyuki ^a   Rayl, Thomas J ^a   Hwang, Inkyu ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL EVALUATION; CATHARANTHINE; COUPLING EFFICIENCY; COUPLING REACTION; DIASTEREO-SELECTIVITY; DIASTEREOSELECTIVE; DIRECT COUPLING; DOUBLE BONDS; FORMYL GROUP; FUNCTIONALIZED; IMINIUM; METHOXY GROUP; METHYL GROUP; NATURAL PRODUCTS; NATURALLY OCCURRING; OXIDATION REACTIONS; OXIDATIVE FRAGMENTATION; OXIDIZED CARBONS; RADICAL CATIONS; REACTION MIXTURE; STRUCTURAL ANALOGUE; TOTAL SYNTHESIS; VINBLASTINE; VINDOLINE;

IRON COMPOUNDS; LABELS; OLEFINS; OXIDATION; STEREOCHEMISTRY; STEREOSELECTIVITY;

GROUP TECHNOLOGY;

16 DESMETHOXYVINBLASTINE; 4 DESACETOXY 16 DESMETHOXYVINBLASTINE; 4 DESACETOXYVINBLASTINE; CATHARANTHINE; DEACETYLVINBLASTINE; DESMETHOXYVINDOLINE; ENAMINE; FERRIC ION; GLYCOPROTEIN P; NAVELBINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; VINDOLINE; BORANE DERIVATIVE; IRON; SODIUM BOROHYDRIDE; VINCA ALKALOID;

ACUTE LEUKEMIA; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CHILDHOOD LEUKEMIA; CYTOTOXICITY; DEUTERON NUCLEAR MAGNETIC RESONANCE; DRUG STRUCTURE; DRUG SYNTHESIS; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; NEUROTOXICITY; NEUTROPENIA; ONE POT SYNTHESIS; OXIDATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOMIMETICS; CHEMISTRY; ISOTOPE LABELING; MOUSE; OXIDATION REDUCTION REACTION; STEREOISOMERISM; SYNTHESIS; TOXICITY; TUMOR CELL LINE;

ANIMALS; BIOMIMETICS; BOROHYDRIDES; CELL LINE, TUMOR; HUMANS; IRON; ISOTOPE LABELING; MICE; OXIDATION-REDUCTION; STEREOISOMERISM; VINBLASTINE; VINCA ALKALOIDS; VINCRISTINE;

EID: 67949110944     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja809842b     Document Type: Article

References (100)

1. Neuss, N., Neuss, M. N. In The Alkaloids; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 229.
2. (a) Noble, R. L.; Beer, C. T.; Cutts, J. H. Ann. N. Y. Acad. Sci. 1958, 76, 882.
3. (b) Noble, R. L. Lloydia 1964, 27, 280.
4. (c) Svoboda, G. H.; Nuess, N.; Gorman, M. J. Am. Pharm. Assoc. Sci. Ed. 1959, 48, 659. For related, naturally occurring bisindole alkaloids: see,
5. (d) Leurosidine: Svoboda, G. H. Lloydia 1961, 24, 173.
6. (e) Deoxyvinblastine: De Bruyn, A.; Sleechecker, J.; De Jonghe, J. P.; Hannart, J. Bull. Soc. Chim. Belg. 1983, 92, 485.
7. (f) Deoxyvinblastine: Neuss, N.; Gorman, M.; Cone, N. J.; Huckstep, L. L. Tetrahedron Lett. 1968, 783.
8. (g) N-Desmethylvinblastine: Simonds, R.; De Bruyn, A.; De Taeye, L.; Verzele, M.; De Pauw, C. Planta Med. 1984, 50, 274.
9. (h) Desacetoxyvinblastine: Neuss, N., Barnes, A. J., Jr.; Huckstep, L. L. Experientia 1975, 31, 18.
10. (i) Desacetylvinblastine: Svoboda, G. H.; Barnes, A. J., Jr. J. Pharm. Sci. 1964, 53, 1227.
11. (a) Owellen, R. I.; Hartke, C. A.; Dickerson, R. M.; Haines, F. O. Cancer Res. 1976, 36, 1499.
12. (b) Pearce, H. L. In The Alkaloids; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 145.
13. (c) Borman, L. S.; Kuehne, M. E. In The Alkaloids; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 133.
14. (d) Fahy, J. Curr. Pharm. Design 2001, 7, 1181.
15. Moncrief, J. W.; Lipscomb, W. N. J. Am. Chem. Soc. 1965, 87, 4963.
16. Barnett, C. J.; Cullinan, G. J.; Gerzon, K.; Hoying, B. C.; Jones, W. E.; Newlon, W. M.; Poore, G. A.; Robison, R. L.; Sweeney, M. J.; Todd, G. C.; Dyke, R. W.; Nelson, R. L. J. Med. Chem. 1978, 21, 88.
17. (a) Mangeney, P.; Andriamialisoa, R. Z.; Lallemand, J.-Y.; Langlois, N.; Langlois, Y.; Potier, P. Tetrahedron 1979, 35, 2175.
18. (b) Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P. Tetrahedron 1980, 36, 3053.
19. (c) Gueritte, F.; Pouilhes, A.; Mangeney, P.; Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P. Eur. J. Med. Chem. 1983, 18, 419.
20. (a) Fahy, J.; Dulfos, A.; Ribet, J.-P.; Jacquesy, J.-C.; Berrier, C.; Jouannetaud, M.-P.; Zunino, F. J. Am. Chem. Soc. 1997, 119, 8576.
21. (b) Hill, B. T.; Fiebig, H.-H.; Waud, W. R.; Poupon, M.-F.; Colpaert, F.; Kruczynski, A. Eur. J. Cancer 1999, 35, 512.
22. (a) Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. Eur. J. Cancer 1993, 29, 1320.
23. (b) Baguley, B. C.; Holdaway, K. M.; Thomsen, L. L.; Zhuang, L.; Zwi, L. J. Eur. J. Cancer 1991, 27, 482.
24. (c) Vacca, A.; Iurlaro, M.; Ribatti, D.; Minschetti, M.; Nico, B.; Ria, R.; Pellegrino, A.; Dammacco, F. Blood 1999, 94, 4143.
25. (a) van der Heijden, R.; Jacobs, D. I.; Snoeijer, W.; Hallard, D.; Verpoorte, R. Curr. Med. Chem. 2004, 11, 607.
26. (b) McCoy, E.; O'Connor, S. E. J. Am. Chem. Soc. 2006, 128, 14276.
27. (a) Gorman, M.; Neuss, N.; Svoboda, G. H.; Barnes, A. J., Jr.; Cone, N. J. J. Am. Pharm. Assoc. Sci. Ed. 1959, 48, 256.
28. (b) Gorman, M.; Neuss, N.; Biemann, K. J. Am. Chem. Soc. 1962, 84, 1058.
29. Reviews: (a) Kuehne, M. E.; Marko, I. In The Alkaloids; Brossi, A., Suffness, M., Eds.; Academic: San Diego, 1990; Vol. 37, p 77.
30. (b) Potier, P. J. Nat. Prod. 1980, 43, 72.
31. (c) Kutney, J. P. Nat. Prod. Rep. 1990, 7, 85.
32. (d) Kutney, J. P. Synlett 1991, 11.
33. (e) Kutney, J. P. Acc. Chem. Res. 1993, 26, 559.
34. (f) Kuehne, M. E.; Bornmann, W. G.; Marko, I.; Qin, Y.; Le Boulluec, K. L.; Frasier, D. A.; Xu, F.; Malamba, T.; Ensinger, C. L.; Borman, L. S.; Huot, A. E.; Exon, C.; Bizzarro, F. T.; Cheung, J. B.; Bane, S. L. Org. Biomol. Chem. 2003, 1, 2120.
35. (a) Potier, P.; Langlois, N.; Langlois, Y.; Gueritte, F. J. Chem. Soc., Chem. Commun. 1975, 670.
36. (b) Langlois, N.; Gueritte, F.; Langlois, Y.; Potier, P. J. Am. Chem. Soc. 1976, 98, 7017.
37. (a) Kutney, J. P.; Ratcliffe, A. H.; Treasurywala, A. M.; Wunderly, S. Heterocycles 1975, 3, 639.
38. (b) Kutney, J. P.; Hibino, T.; Jahngen, E.; Okutani, T.; Ratcliffe, A. H.; Treasurywala, A. M.; Wunderly, S. HelV. Chim. Acta 1976, 59, 2858.
39. Mangeney, P.; Andriamialisoa, R. Z.; Langlois, N.; Langlois, Y.; Potier, P. J. Am. Chem. Soc. 1979, 101, 2243.
40. Kutney, J. P.; Choi, L. S. L.; Nakano, J.; Tsukamoto, H.; McHugh, M.; Boulet, C. A. Heterocycles 1988, 27, 1845.
41. (a) Neuss, N.; Gorman, M.; Cone, N. J.; Huckstep, L. L. Tetrahedron Lett. 1968, 783.
42. (b) Atta-ur-Rahman, Pak. J. Sci. Ind. Res. 1971, 14, 487.
43. (c) Kutney, J. P.; Beck, J.; Bylsma, F.; Cook, J.; Cretney, W. J.; Fuji, K.; Imhof, R.; Treasurywala, A. M. HelV. Chim. Acta 1975, 58, 1690.
44. (a) Magnus, P.; Stamford, A.; Ladlow, M. J. Am. Chem. Soc. 1990, 112, 8210.
45. (b) Magnus, P.; Mendoza, J. S.; Stamford, A.; Ladlow, M.; Willis, P. J. Am. Chem. Soc. 1992, 114, 10232.
46. (a) Kuehne, M. E.; Matson, P. A.; Bornmann, W. G. J. Org. Chem. 1991, 56, 513.
47. (b) Bornmann, W. G.; Kuehne, M. E. J. Org. Chem. 1992, 57, 1752.
48. (c) Kuehne, M. E.; Zebovitz, T. C.; Bornmann, W. G.; Marko, I. J. Org. Chem. 1987, 52, 4340.
49. Schill, G.; Priester, C. U.; Windhovel, U. F.; Fritz, H. Tetrahedron 1987, 43, 3765.
50. (a) Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, H.; Fukuyama, T. J. Am. Chem. Soc. 2002, 124, 2137.
51. (b) Kuboyama, T.; Yokoshima, S.; Tokuyama, H.; Fukuyama, T. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11966.
52. (c) Miyazaki, T.; Yokoshima, S.; Simizu, S.; Osada, H.; Tokuyama, H.; Fukuyama, T. Org. Lett. 2007, 9, 4737.
53. (a) Choi, Y.; Ishikawa, H.; Velcicky, J.; Elliott, G. I.; Miller, M. M.; Boger, D. L. Org. Lett. 2005, 7, 4539.
54. (b) Ishikawa, H.; Elliott, G. I.; Velcicky, J.; Choi, Y.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 10596.
55. (a) Vukovic, J.; Goodbody, A. E.; Kutney, J. P.; Misawa, M. Tetrahedron 1988, 44, 325.
56. (b) For an analogous electrochemical coupling (0.6 V in buffer; NaBH4) to provide anhydrovinblastine (9), see Gunic, E.; Tabakovic, I.; Gasic, M. J. J. Chem. Soc., Chem. Commun. 1993, 1496.
57. (c) For the development of an enzymatic coupling reaction to provide anhydrovinblastine (9), see Sagui, F.; Chirivi, C.; Fontana, G.; Nicotra, S.; Passarella, D.; Riva, S.; Danieli, B. Tetrahedron 2009, 65, 312.
58. (a) Sakamoto, N.; Tan, H.; Hata, E.; Kihara, N. JP 04164087, 1992; Chem. Abstr. 1992, 117, 192139.
59. (b) Tan, H.; Sakamoto, N.; Hata, E.; Ishitoku, T.; Kihara, N. US 5037977, 1990; Chem. Abstr. 1990, 113, 6663.
60. Ishikawa, H.; Colby, D. A.; Boger, D. L. J. Am. Chem. Soc. 2008, 130, 420.
61. (a) Scott, A. I.; Gueritte, F.; Lee, S. L. J. Am. Chem. Soc. 1978, 100, 6253.
62. (b) McLauchlan, W. R.; Hasan, M.; Baxter, R. L.; Scott, A. I. Tetrahedron 1983, 39, 3777.
63. Goodbody, A. E.; Watson, C. D.; Chapple, C. C. S.; Vukovic, J.; Misawa, M. Phytochemistry 1988, 27, 1713.
64. For additional seminal studies on the Fe(III)-coupling to provide anhydrovinblastine, see: (a) Szantay, C., Jr.; Balazs, M.; Bolcskei, H.; Szantay, C. Tetrahedron 1991, 47, 1265.
65. (b) Sundberg, R. J.; Hong, J.; Smith, S. Q.; Sabat, M.; Tabakovic, I. Tetrahedron 1998, 54, 6259.
66. Sundberg, R. J.; Gadamasetti, K.; Hunt, P. J. Tetrahedron 1992, 48, 277.
67. (a) Langlois, N.; Potier, P. J. Chem. Soc., Chem. Commun. 1978, 102.
68. (b) Langlois, N.; Potier, P. J. Chem. Soc., Chem. Commun. 1979, 582.
69. For example, see: (a) Kutney, J. P.; Balsevich, J.; Bokelman, G. H.; Hibino, T.; Honda, T.; Itoh, I.; Ratcliffe, A. H.; Worth, B. R. Can. J. Chem. 1978, 56, 62.
70. Kutney, J. P.; Choi, L. S. L.; Nakano, J.; Tsukamoto, H.; McHugh, M.; Boulet, C. A. Heterocycles 1988, 27, 1845.
71. (a) Kutney, J. P.; Choi, L. S. L.; Nakano, J.; Tsukamoto, H. Heterocycles 1988, 27, 1827.
72. (b) Kutney, J. P.; Choi, L. S. L.; Nakano, J.; Tsukamoto, H. Heterocycles 1988, 27, 1837.
73. (c) Mukaiyama, T.; Isayama, S.; Inoki, S.; Kato, K.; Yamada, T.; Takai, T. Chem. Lett. 1989, 449.
74. (a) Isayama, S.; Mukaiyama, T. Chem. Lett. 1989, 1071.
75. (b) Tokuyasa, T.; Kunikawa, S.; Masuyama, A.; Nojima, M. Org. Lett. 2002, 4, 3595.
76. Glavee, G. N.; Klabunde, K. J.; Sorensen, C. M.; Hadjipanayis, G. C. Inorg. Chem. 1995, 34, 28.
77. Collman, J. P.; Finke, R. G.; Matlock, P. L.; Wahren, R.; Komoto, R. G.; Brauman, J. I. J. Am. Chem. Soc. 1978, 100, 1119.
78. Sugimori, T.; Horike, S.-I.; Tsumura, S.; Handa, M.; Kasugu, K. Inorg. Chim. Acta 1998, 283, 275.
79. (a) Ashby, E. C.; Lin, J. J. J. Org. Chem. 1978, 43, 2567.
80. (b) Lin, R.; Zhang, Y. Syn. Commun. 1987, 17, 1403.
81. (c) Kashima, C.; Yamamoto, Y. Chem. Lett. 1978, 1285.
82. Snider, B. B.; Duvall, J. R. Org. Lett. 2004, 6, 1265.
83. Kato, K.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 1991, 64, 2948.
84. The single-crystal X-ray structure of 28 establishing its structure and relative stereochemistry was derived from off-white crystals obtained from EtOAc and has been deposited with the Cambridge Crystallographic Data Centre (CCDC 713670).
85. (a) Miller, J. C.; Gutowski, G. E.; Poore, G. A.; Boder, G. B. J. Med. Chem. 1977, 20, 409.
86. (b) Miller, J. C.; Gutowski, G. E. Ger Patent 2753791-19780608 (Chem. Abstr. 1978, 89, 129778).
87. (c) Gerzon, K.; Miller, J. C. Eur. Patent 55602 (Chem. Abstr. 1982, 97, 163310).
88. (d) Review of superacid functionalization: Duflos, A.; Kruczynski, A.; Barret, J.-M. Curr. Med. Chem.-Anti-Cancer Agents 2002, 2, 55.
89. The substrates 33 and 34 were prepared utilizing the tandem [4 + 2]/[3 + 2] 1,3,4-oxadiazole cycloaddition cascade as detailed in the Supporting Information with a chromatographic resolution.
90. Bolcskei, H.; Gacs-Baitz, E.; Szantay, C. Tetrahedron Lett. 1989, 30, 7245.
91. Balazs, M.; Szantay, C., Jr.; Bolcskei, H.; Szantay, C. Tetrahedron Lett. 1993, 34, 4397.
92. Goodbody, A. E.; Watson, C. D.; Misawa, M. Chem. Abstr. 1992, 116, 235944.
93. Elliott, G. I.; Velcicky, J.; Ishikawa, H.; Li, Y.; Boger, D. L. Angew. Chem., Int. Ed. 2006, 45, 620.
94. Yuan, Z.; Ishikawa, H.; Boger, D. L. Org. Lett. 2005, 7, 741.
95. Ishikawa, H.; Boger, D. L. Heterocycles 2007, 72, 95.
96. Johnson, I. S.; Hargrove, W. W.; Harris, P. N.; Wright, H. F.; Boder, G. B. Cancer Res. 1966, 26, 2431.
97. (a) Dumontet, C.; Sikic, B. I. J. Clin. Oncol. 1999, 17, 1061.
98. (b) Kavallaris, M.; Verrills, N. M.; Hill, B. T. Drug Res. Updates 2001, 4, 392.
99. (a) Elliott, G. I.; Fuchs, J. R.; Blagg, B. S. J.; Ishikawa, H.; Yuan, Z.-Q.; Tao, H.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 10589.
100. (b) Wilkie, G. D.; Elliott, G. I.; Blagg, B. S. J.; Wolkenberg, S. E.; Soenen, D. R.; Miller, M. M.; Pollack, S.; Boger, D. L. J. Am. Chem. Soc. 2002, 124, 11292.